中新网上海4月19日电 (记者 陈静)记者今日从上海医疗界获悉，中国医学专家在肺癌治疗领域取得重大突破，成功实施了“免疫+化疗”的创新治疗模式，为晚期肺鳞癌患者带来了新的生机。
据了解，长期以来，晚期肺鳞癌的治疗一直面临诸多挑战，传统疗法效果有限，患者生存期短。上海的医学专家团队在深入研究后，提出将免疫疗法与化疗相结合的新策略，旨在激活患者自身的免疫系统，同时通过化疗抑制肿瘤生长，以达到更好的治疗效果。
据参与此项研究的专家介绍，这种“免疫+化疗”的新模式已经在部分晚期肺鳞癌患者身上得到验证，一些患者的病情得到了显著改善，生存期明显延长。这一疗法的出现，不仅为患者提供了新的治疗选择，也对肺癌治疗领域产生了深远影响。
目前，该治疗模式尚处于临床试验阶段，专家们正在积极收集数据，以进一步评估其安全性和有效性。未来，他们计划将这一创新疗法推广至更广泛的患者群体，让更多晚期肺鳞癌患者受益。
此次突破性的研究成果，标志着中国在肺癌治疗领域又迈出了坚实的一步，也体现了中国医疗科研团队在攻克重大疾病上的不懈努力和卓越贡献。
英语如下：
**News Title:** “Shanghai Experts Pioneer ‘Immunotherapy + Chemotherapy’ Breakthrough Treatment, Offering New Hope to Late-Stage Lung Squamous Cell Carcinoma Patients”
**Keywords:** Immunotherapy, Late-Stage Lung Squamous Cell Carcinoma, Treatment Breakthrough
**News Content:**
SHANGHAI, China, April 19 (Xinhua) — Chinese medical experts have made a significant breakthrough in lung cancer treatment, introducing an innovative “immunotherapy + chemotherapy” approach, offering a lifeline to patients with late-stage lung squamous cell carcinoma, according to sources in Shanghai’s medical community.
For a long time, treating late-stage lung squamous cell carcinoma has posed numerous challenges, with conventional therapies proving limited in effectiveness and resulting in short survival periods. A team of medical experts in Shanghai, after extensive research, proposed a new strategy combining immunotherapy with chemotherapy, aiming to activate patients’ immune systems while suppressing tumor growth through chemotherapy for improved outcomes.
According to the experts involved in the study, this “immunotherapy + chemotherapy” approach has shown promise in some late-stage patients, with notable improvements in their conditions and significant extensions in their survival times. This therapy not only provides a new treatment option for patients but also has a profound impact on the field of lung cancer treatment.
Currently, the treatment model is still in the clinical trial phase, and experts are actively collecting data to further assess its safety and efficacy. In the future, they plan to extend this innovative therapy to a broader patient population, benefiting more late-stage lung squamous cell carcinoma patients.
This groundbreaking achievement signifies another robust stride forward for China in the treatment of lung cancer and underscores the relentless efforts and outstanding contributions of China’s medical research teams in tackling major diseases.
【来源】http://www.chinanews.com/life/2024/04-19/10202239.shtml
Views: 1